Tarsus Pharmaceuticals completes acquisition of Alkeus, adding Stargardt Phase 3 drug
Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine targeting Stargardt’s disease biology. The deal strengthens its eye-care pipeline.